Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer.
Adult
Anthracyclines
/ adverse effects
Antibiotics, Antineoplastic
/ adverse effects
Breast Neoplasms
/ drug therapy
Cardiac Imaging Techniques
Cardiotoxicity
Chemotherapy, Adjuvant
Databases, Factual
Early Diagnosis
Female
Heart Diseases
/ chemically induced
Humans
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Registries
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States
/ epidemiology
Young Adult
Adverse events
Biological therapy
Breast cancer
Cardiotoxicity
Cardiovascular disease
Cardiovascular imaging
Chemotherapy
Diagnostic imaging
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
18
01
2020
accepted:
05
05
2020
pubmed:
28
5
2020
medline:
21
10
2020
entrez:
28
5
2020
Statut:
ppublish
Résumé
We investigated time trends and factors associated with the use of cardiac imaging among women with early-stage breast cancer prior to the initiation of treatment. Of 11,732 women ages 24-64, diagnosed with stage I-III breast cancer in 2006-2011, 2550 (22%) received anthracycline-based chemotherapy. Baseline cardiac imaging was used in 79% of patients receiving anthracyclines and increased over time. Of 2277 (20%) women who received non-anthracycline therapy, 16% received cardiac imaging. Women receiving cardiac imaging in non-anthracycline therapy group were more likely to have higher cardiovascular risk, as well as higher cancer stage and worse histological tumor grade suggesting that results of imaging might have influenced the choice of cancer therapy. Our findings indicate the need for cardio-oncology collaboration in identification and treatment of women at high risk for adverse oncology and cardiovascular outcomes.
Identifiants
pubmed: 32458402
doi: 10.1007/s12265-020-10023-6
pii: 10.1007/s12265-020-10023-6
doi:
Substances chimiques
Anthracyclines
0
Antibiotics, Antineoplastic
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-489Subventions
Organisme : NIH HHS
ID : R01CA160671
Pays : United States
Organisme : National Institutes of Health (US)
ID : P30CA051008
Pays : International